

Oppose Maryland House Bill 631!

aam
Association for Accessible Medicines

Don't Harm Patient Access to Affordable Generic Medicines by Chilling Generic Drug Competition.

Everyone supports proposals to control rising prescription drug prices, but H.B. 631 would just make the problem worse for Maryland patients and our economy.

H.B. 631 ignores the realities of the prescription drug marketplace.

Inexplicably, the bill only applies to generic drugs – products that save the state, taxpayers and patients billions per year – not much more expensive brand-name and specialty drugs that cost Maryland patients and tax-payers billions of dollars per year.

- Generics saved Maryland \$3.7 billion, including state programs and your tax dollars – in just one year alone.
- Generic drugs are a true success story. Generic medicines account for 90% of all prescriptions, but they only account for 27% of drug costs.

H.B. 631 has no meaningful standard to allow companies to know when they are in compliance with the law.

The bill does not define when a price is “not justified” or “excessive.”

- Given the vague standards set forth in the bill, companies would perpetually be at risk of facing prosecution for price fluctuation of just pennies - that can normally occur during the course of business within the competitive free market.
- Without a true standard dictating when a free market price is “justified,” H.B. 631 would provide no notice for companies to know whether they are in compliance with the new law.
- Without clear guidance under the law, companies will need to find ways to mitigate the risk of costly litigation with the Attorney General, putting patient access to affordable to generics at risk.
- The bill currently creates an “unconscionable” standard which only allows for changes in price when a manufacturer has changes in the direct cost of production or expands marketing costs for its product. There is no allowance for a manufacturer to make reasonable business decisions based on existing market dynamics.



In Maryland, generics save...

Medicaid:	\$698 million
Medicare:	\$807 million
Cash (Non-Insured)	\$205 million
Commercial Insured:	\$2 billion
Total	\$3.7 billion


H.B. 631 would chill competition among generic drug manufacturers and allow government bureaucrats to influence the healthcare marketplace, ultimately driving up costs.

The bill allows the government to impose costs and regulatory burdens whenever bureaucrats believe that pricing of a medicine is “not justified.”

- Year over year, generic drug prices fall, while brand name drug prices rise. The overall price of generics fell over 8% in 2016, and prices are down over 70% since 2008. Rather than allow market competition to continue working, Maryland would become the first state to reject generic competition in favor of more government regulation – of generic drugs, the only segment of health care costs that are declining.
- Generic drug prices can fluctuate up and down in the commoditized generic prescription drug marketplace over the course of days or months while still declining on average. But this bill does not account for market realities and instead puts elected officials in the role of the marketplace.
- By subjecting manufacturers of generic drugs to draconian penalties – while ignoring the substantial costs of brand-name prescription drugs – the policy in H.B. 631 would provide an incentive for generic drug companies to avoid doing business in or selling their products in our state.
- If fewer affordable generic drugs are available in Maryland, we all lose.

EXPRESS SCRIPTS PRESCRIPTION PRICE INDEX

2016



Market Dynamics

Year over year, generic drug prices fall, while brand name drug prices rise. The overall price of generics fell over 8% in 2016, and prices are down over 70% since 2008.